Cellipont Bioservices ’ Texas facility has supported cell therapy projects to date that are expected to reach an IND submission in 2026.

Cellipont Bioservices is a cell therapy CDMO focused on helping innovative developers advance complex cell therapy programs from development through cGMP manufacturing. Our team brings deep technical expertise across process development, analytical services, technology transfer, manufacturing, quality control, stability, and sterile fill/finish. We have extensive experience working with challenging cell types and advanced therapy platforms, including CAR-T, iNK, dendritic cells, and other novel cell therapy approaches. What sets Cellipont apart is the combination of technical depth and highly responsive, hands-on partnership. Our experienced team has supported more than 18,000 tissue samples and 900+ primary cell cultures and brings decades of experience from advanced therapy organizations of all sizes. Our GMP-compliant facilities and quality systems are designed to support programs as they progress from early development into clinical manufacturing and beyond. We work closely with our clients to solve manufacturing challenges, build robust and scalable processes, and keep programs moving toward patients. At Cellipont, we believe manufacturing is more than an outsourced service—it is an essential part of a therapy’s path to success. Our name reflects that mission. “Cellipont” combines cell with pont, the Latin root for bridge. We bridge innovative science with patients, technical excellence with personal service, and our team’s passion with the work of advancing life-changing therapies. Bridging innovation to cure.